Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries., CA Cancer J Clin, 68, 394, 10.3322/caac.21492

Zhang, 2003, Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer., N Engl J Med, 348, 203, 10.1056/NEJMoa020177

Sato, 2005, Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer., Proc Natl Acad Sci U S A, 102, 18538, 10.1073/pnas.0509182102

Curiel, 2004, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival., Nat Med, 10, 942, 10.1038/nm1093

Matsuzaki, 2010, Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer., Proc Natl Acad Sci U S A, 107, 7875, 10.1073/pnas.1003345107

Varga, 2019, Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028., Gynecol Oncol, 152, 243, 10.1016/j.ygyno.2018.11.017

Liu, 2019, Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial., JAMA Oncol, 5, 1731, 10.1001/jamaoncol.2019.3343

McDermott, 2013, PD-1 as a potential target in cancer therapy., Cancer Med, 2, 662, 10.1002/cam4.106

Matulonis, 2019, Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study., Ann Oncol, 30, 1080, 10.1093/annonc/mdz135

Fukumura, 2018, Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges., Nat Rev Clin Oncol, 15, 325, 10.1038/nrclinonc.2018.29

Motz, 2014, Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors., Nat Med, 20, 607, 10.1038/nm.3541

André, 2014, Metronomics: towards personalized chemotherapy?, Nat Rev Clin Oncol, 11, 413, 10.1038/nrclinonc.2014.89

Garcia, 2008, Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia., J Clin Oncol, 26, 76, 10.1200/JCO.2007.12.1939

Wolchok, 2009, Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria., Clin Cancer Res, 15, 7412, 10.1158/1078-0432.CCR-09-1624

Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)., Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026

Greimel, 2003, An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer., Eur J Cancer, 39, 1402, 10.1016/S0959-8049(03)00307-1

Burger, 2007, Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study., J Clin Oncol, 25, 5165, 10.1200/JCO.2007.11.5345

Brown, 2001, Interval estimation for a binomial proportion., Statist Sci, 10.1214/ss/1009213286

Huang, 2012, Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy., Proc Natl Acad Sci U S A, 109, 17561, 10.1073/pnas.1215397109

Ghiringhelli, 2007, Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients., Cancer Immunol Immunother, 56, 641, 10.1007/s00262-006-0225-8

Matulonis, 2018, Phase II study of pembrolizumab (Pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer., Gynecol Oncol., 149, 24, 10.1016/j.ygyno.2018.04.059

Walsh, 2019, Phase II trial of pembrolizumab with cisplatin and gemcitabine in women with recurrent platinum-resistant ovarian cancer., Gynecol Oncol, 154, 16, 10.1016/j.ygyno.2019.04.043

Zamarin, 2020, Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG Oncology Study., J Clin Oncol, 38, 1814, 10.1200/JCO.19.02059

Konstantinopoulos, 2019, Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma., JAMA Oncol, 5, 1141, 10.1001/jamaoncol.2019.1048

Lee, 2017, Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1-3 inhibitor cediranib in women’s cancers: a dose-escalation, phase I study., J Clin Oncol, 35, 2193, 10.1200/JCO.2016.72.1340

Disis, 2019, Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN Solid Tumor Trial., JAMA Oncol, 5, 393, 10.1001/jamaoncol.2018.6258

Roncolato, 2017, Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy., Ann Oncol, 28, 1849, 10.1093/annonc/mdx229

2018

Burger

National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Published November 27, 2017. Accessed March 1, 2019. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50